Sunitinib
Sunitinib
Definition
An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.
Also known as 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, SUNITINIB — per NCIT
Also identified as
- ATC L01EX per NCIT
- NCIT NCIT:C71622 per NCIT
Indications
| Disease | Relation | Source |
|---|---|---|
| Gastrointestinal stromal tumor | may treat | MEDRT · Public domain (U.S. Government work) |
| Neuroendocrine neoplasm | may treat | MEDRT · Public domain (U.S. Government work) |
| Pancreatic neoplasm | may treat | MEDRT · Public domain (U.S. Government work) |
| Renal cell carcinoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Endocrine gland | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.